Recent advances in tyrosine kinase inhibitors

被引：40

作者：

Fry, DW

机构：

[1] Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company Ann, Arbor

来源：

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 31 | 1996年 / 31卷

关键词：

D O I：

10.1016/S0065-7743(08)60455-8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：151 / 160

页数：10

共 62 条

[1] GROWTH-FACTORS AND CANCER [J].

AARONSON, SA .

SCIENCE, 1991, 254 (5035) :1146-1153

[2]

Barker A., 1993, Patent, Patent No. [EP0566226, 0566226]

[3]

BARKER AJ, 1993, Patent No. 602851

[4]

BARKER AJ, 1995, Patent No. 635507

[5]

BARKER AJ, 1992, Patent No. 520722

[6]

BARKER AJ, 1994, Patent No. 635498

[7] Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolines [J].

Bridges, AJ ;

Cody, DR ;

Zhou, HR ;

McMichael, A ;

Fry, DW .

BIOORGANIC & MEDICINAL CHEMISTRY, 1995, 3 (12) :1651-1656

[8] Tyrosine kinase inhibitors .8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor [J].

Bridges, AJ ;

Zhou, H ;

Cody, DR ;

Rewcastle, GW ;

McMichael, A ;

Showalter, HDH ;

Fry, DW ;

Kraker, AJ ;

Denny, WA .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (01) :267-276

[9]

BRIDGES AJ, 1995, EXPERT OPIN THER PAT, V5, P1245

[10] CELL-SIGNALING TARGETS FOR ANTITUMOR DRUG DEVELOPMENT [J].

BRUNTON, VG ;

WORKMAN, P .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (01) :1-19

← 1 2 3 4 5 6 7 →